Impact of non-canonical ALK fusion on the efficacy of targeted therapy in non-small cell lung cancer-Reference-Cited by-同舟云学术

Impact of non-canonical ALK fusion on the efficacy of targeted therapy in non-small cell lung cancer

Published:2023-11-29 Issue: Volume: Page:
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Zeng Hao¹,Wei Qi¹,Tang Yuan²,Zhang Yuanyuan¹,Tan Sihan¹,Huang Qin¹³,Pu Xin¹³,Li Yalun³⁴,Tian Panwen³⁴

Affiliation:

1. Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

2. Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

3. Department of Pulmonary and Critical Care Medicine, Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

4. Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference5 articles.

1. Prevalence and clinical impact of concomitant mutations in anaplastic lymphoma kinase rearrangement advanced non-small-cell lung cancer (Guangdong Association of Thoracic Oncology Study 1055);Front Oncol,2020

2. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence;Cancer Med,2022

3. Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers;J Transl Med,2021

4. Complex ALK fusions are associated with better prognosis in advanced non-small cell lung cancer;Front Oncol,2020

5. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer;Mod Pathol,2018